Maintenance Versus Reduction of Immunosuppression in Renal Transplant Recipients with Aggressive Squamous Cell Carcinoma

Dermatologic Surgery

Volumn 30, Issue 4 II, 2004, Pages 674-678

  Moloney, Fergal J ^a   Kelly, P O ^a   Kay, E W ^a   Conlon, P ^a   Murphy, G M ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER INHIBITION; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEAD CANCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MALE; METASTASIS POTENTIAL; NECK CANCER; PRIORITY JOURNAL; SKIN CARCINOMA; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

EID: 1942508212     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2004.00155.x     Document Type: Article

References (19)

1. Jensen P, Moller B, Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 2000;42(2 Pt 1):307.
2. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5636 patients following organ transplantation. Br J Dermatol 2000;143:513-9.
3. Euvrard S, Kanitakis J, Pouteil-Noble C, Claudy A, Touraine JL. Skin cancers in organ transplant recipients. Ann Transplant 1997;2:28-32.
4. Gibson GE. Evaluation of Risk Factors for Cutaneous Malignancy in Renal Transplant Recipients [dissertation]. Cork, Ireland: National University of Ireland, 1995.
5. Lund HZ. How often does squamous cell carcinoma of the skin metastasize? Arch Dermatol 1965;92:635-7.
6. Euvrard S, Kanitakis J, Chardonnet Y, et al. External anogenital lesions in organ transplant recipients. Arch Dermatol 1997;133:175-8.
7. Euvrard S, Kanitakis J, Pouteil-Noble C, Distant F. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 1995;27:1767-8.
8. Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: The Australian experience. Cancer 1999;85:1758-64.
9. Nguyen P, Vin-Christian K, Ming M, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002;138:758-63.
10. Gupta AK, Cardella CJ, Habermann HF. Cutaneous malignant neoplasm in patients with renal transplants. Arch Dermatol 1986;122:1288-93.
11. Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003;139:301-6.
12. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
13. Shimm DS, Wilder RB. Radiation therapy for squamous cell carcinoma of the skin. Am J Clin Oncol 1991;14:383-6.
14. Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000;36:167-76.
15. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996;61:715-21.
16. Soulillou JP, Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001;72(12 Suppl):S89-93.
17. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001;137:459-63.
18. Aichberger C, Eberl T, Riedmann B, et al. Long-term outcome after switch from cyclosporine-based triple-drug immunosuppression to double therapy at three months. Clin Transplant 1996;10:209-12.
19. Matl I, Lacha J, Simova M, et al. Withdrawal of steroids from triple-drug therapy in kidney transplant patients. Nephrol Dial Transplant 2000;15:1041-5.